

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER**

Reference is made to the relevant announcement of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated August 2, 2021 in relation to, among other things, the Proposed Amendments to the Articles of Association (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The board of directors (the “**Board**”) of the Company hereby announces that on August 2, 2021, at the eighteenth meeting of the second session of the Board, it has resolved and approved, among other things, the appointment of co-chief executive officer of the Company.

To further harness the power of the Company’s integrated and end-to-end capabilities across research, development, manufacturing, testing and clinical trials, we plan to conduct organizational structure alignments, and appoint an additional co-chief executive officer.

In light of the above, the Board is pleased to announce it has, subject to the approval of the Proposed Amendments to the Articles of Association by way of special resolution of the Shareholders at the EGM (the “**Approval**”), appointed Dr. Minzhang Chen (陳民章) (“**Dr. Chen**”) as an additional co-chief executive officer of the Company. The term of office of Dr. Chen as co-chief executive officer will take effect from the date of the Approval until the expiry of the term of the second session of the Board (the “**Term**”).

Dr. Chen, being the co-chief executive officer of the Company, is responsible for leading WuXi Chemistry, the chemistry business segment of the Company, and integrating the chemistry business-related resources and capabilities of the Company, including Shanghai SynTheAll Pharmaceutical Co., Ltd. (“WuXi STA”), the Chemistry Service Unit (CSU), the International Discovery Service Unit (IDSU) and the Core Analytical Services (CAS) business units. Dr. Chen will lead the new WuXi Chemistry organization to expedite the execution of our new CRDMO (Contract Research Development Manufacturing Organization) strategy and further enhance our global competitiveness in Chemistry-related fields.

Dr. Steve Qing Yang, the other co-chief executive officer of the Company, is responsible for leading WuXi Biology, the biology business segment of the Company, and integrating the cutting-edge technologies of the Company in DNA-encoded library (DEL), biology, oncology and immunology in order to provide global customers with supreme integrated drug discovery and research services. He is also responsible for leading WuXi Testing, the testing business segment of the Company, and integrating the preclinical and clinical resources and capabilities of the Company, such as Lab Testing Division, WuXi Clinical (康德弘翼) (Clinical Development Services business) and WuXi SMO (藥明津石) (Site Management Organization business), so as to better serve our global customers in biotech, pharmaceutical, medical device, and in vitro diagnostic sectors.

The Board would like to take this opportunity to welcome Dr. Chen to serve as a co-chief executive officer of the Company. The biographical details of Dr. Chen are set out as follows:

**Dr. Minzhang Chen (陳民章)**, aged 52, is currently a vice president of the Company. He joined the Group in 2008.

Since 1997, he has had over 20 years of experience in the research and development and production management of new drugs. From 1997 to 2008, he served as the chief researcher of the chemistry department of Schering-Plough Research Institute (先靈葆雅研究所) and the head of the technical operation department of Vertex Pharmaceuticals Inc. Dr. Chen has been serving as a director and chief executive officer of WuXi STA, a principal subsidiary of the Company, since August 2011 and became the vice president of the Company in March 2020. He is responsible for leading the chemistry business segment of the Company, i.e. WuXi Chemistry, and integrating the chemistry business-related resources and capabilities of the Company, including WuXi STA and the Chemistry Service Unit (CSU).

Dr. Chen obtained a bachelor’s degree in chemistry from Peking University (北京大學) in the PRC in 1991. He also obtained a Ph. D. degree in Organic Chemistry from University of Minnesota in the U.S. in 1996.

As at the date of this announcement, Dr. Chen has an interest in 42,579 H Shares (adjusted pursuant to the issuance of 2 new Shares for every 10 Shares by way of capitalization of reserve under the profit distribution plan of the Company for the year ended December 31, 2020) as the underlying Shares of the award granted to him pursuant to the H share award and trust scheme adopted by the Company. For further details, please refer to (i) the announcements of the Company dated July 21, 2020, August 31, 2020 and December 16, 2020; (ii) the circulars of the Company dated August 12, 2020 and April 9, 2021; and (iii) the poll results announcement of the Company dated May 13, 2021.

Dr. Chen has entered into an employment contract with the Company in relation to his role as a vice president for a term commencing on March 24, 2020 and ending on May 14, 2023. Dr. Chen will enter into a separate service contract with the Company in relation to his appointment as a co-chief executive officer for the Term. The remuneration of Dr. Chen in relation to his roles in the Company and WuXi STA is determined by the Board according to the remuneration policy of the Company and with reference to factors including his qualifications and experience, being approximately RMB7,079,900 (before tax) for the year ended December 31, 2020. Subsequent to his appointment as a co-chief executive officer of the Company, the remuneration of Dr. Chen will be subject to adjustment in accordance with the remuneration policy of the Company and with reference to factors including his qualifications and experience.

Save as disclosed above, Dr. Chen (i) does not have any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any other major appointments and professional qualifications; (v) does not have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (vi) has no other information that needs to be disclosed pursuant to Rules 13.51(2) (h) to (v) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited; and (vii) has no other matter that needs to be brought to the attention of the Shareholders.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, August 2, 2021

*As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.*

\* *For identification purposes only*